接受抗逆转录病毒治疗的HIV感染者心肌脂肪变性的特征与危险因素
中位含量为0.59%,52%的患者心肌脂肪变性增加,22%显著增加;年龄、BMI≥25、低CD4最低值和静脉吸毒史与风险相关。
要点
- 接受抗逆转录病毒治疗的HIV感染者中心肌脂肪变性普遍存在。
- BMI≥25 kg/m²和年龄与显著心肌脂肪变性风险独立相关。
- 低CD4最低值和静脉吸毒史可能增加心肌脂肪变性风险。
核心结论
- 相当比例的接受抗逆转录病毒治疗的HIV感染者存在心肌脂肪变性,年龄、BMI≥25 kg/m²、低CD4最低值和静脉吸毒史可能是其危险因素。
主要发现
- 心肌甘油三酯含量中位数(Q1,Q3)为0.59%(0.28%,1.15%)。
- 52%的参与者心肌甘油三酯含量增加(>0.5%),22%显著增加(>1.5%)。
临床怎么用
- 对接受抗逆转录病毒治疗的HIV感染者,尤其是年龄较大、超重/肥胖、CD4最低值低或有静脉吸毒史者,应关注心肌脂肪变性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart failure precursor. We aimed to characterize myocardial steatosis and associated potential risk factors among a subset of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) participants. METHODS: Eighty-two PWH without known heart failure successfully underwent cardiovascular magnetic resonance spectroscopy, yielding data on intramyocardial triglyceride (IMTG) content (a continuous marker for myocardial steatosis extent). Logistic regression models were applied to investigate associations between select clinical characteristics and odds of increased or markedly increased IMTG content. RESULTS: Median (Q1, Q3) IMTG content was 0.59% (0.28%, 1.15%). IMTG content was increased (> 0.5%) among 52% and markedly increased (> 1.5%) among 22% of participants. Parameters associated with increased IMTG content included age (P = .013), body mass index (BMI) ≥ 25 kg/m2 (P = .055), history of intravenous drug use (IVDU) (P = .033), and nadir CD4 count < 350 cells/mm³ (P = .055). Age and BMI ≥ 25 kg/m2 were additionally associated with increased odds of markedly increased IMTG content (P = .049 and P = .046, respectively). CONCLUSIONS: A substantial proportion of antiretroviral therapy-treated PWH exhibited myocardial steatosis. Age, BMI ≥ 25 kg/m2, low nadir CD4 count, and history of IVDU emerged as possible risk factors for myocardial steatosis in this group. CLINICAL TRIALS REGISTRATION: NCT02344290; NCT03238755.
引用
- Neilan TG, Nguyen KL, Zaha VG, et al. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020. PMID: 32645158. doi:10.1093/infdis/jiaa245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。